Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | OGA | O60502 | 2/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533195 | 0.85 | HRH3 (0.49) | HRH3 | |
| SCHEMBL12549962 | 0.83 | HRH3 (0.75) | HRH3 | |
| SCHEMBL13391005 | 0.71 | ACKR3 (0.47) | TBK1 | |
| SCHEMBL12549961 | 0.71 | HRH3 (1.00) | HRH3 | |
| SCHEMBL13003545 | 0.70 | ACKR3 (0.41) | TBK1 | |
| SCHEMBL13409599 | 0.70 | ACKR3 (0.40) | TBK1 | |
| SCHEMBL14077861 | 0.70 | ACKR3 (0.45) | TBK1 | |
| SCHEMBL14078571 | 0.70 | ACKR3 (0.47) | TBK1 | |
| SCHEMBL14077794 | 0.70 | ACKR3 (0.47) | TBK1 | |
| SCHEMBL14456969 | 0.69 | TBK1 (0.41) | TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | GPR119, OXER1, INSR | HRH3 120/4885OGA 61/4885TBK1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.